Episode 970: I'm Buying More of This Stock! Bloom Enerhy, Adicet Bio, Google, Thermo Fisher TMO

**Martin** (0:00)
I don't think Pouchy did anything wrong. I think you guys go get your boosters. I think gain of function research is awesome. I do it in my basement. You got a problem? Who wouldn't want to gain some functions? So Bloom Energy had a monster quarter, man. I didn't realize just what kind of business this was. So these guys obviously provide energy for data centers, devices, which provide energy. I think they're basically batteries, but I'm not sure. But the growth is incredible. I've traded this stock, idiotically. But yeah, the revenue growth is amazing. And the stocks that are been in this part of this kind of boom or doom. So yeah, let's see, 54
It's pretty low margin is the issue, but cash flow is actually not so horrible. So if you say call it 300 cash flow from operations, it's growing very rapidly.
It's actually quite reasonable valuation. It's just a question of one of the big questions for this entire field is, are we seeing businesses that just exist for the AI boom and will never happen again? So imagine you're a data labeling business or a model router or something like that. You exist for this new opportunity, but will you exist in 10 years? Now, obviously, smart business people try to, OK, that's free cash flow from two quarters. So let's make that clear. And that's not free cash flow, that's just cash flow. So maybe a little bit of number budging there, get a little overzealous. So yeah, it's 300 for the full year. Free cash flow more like, let's see, yeah, more like 150, maybe 200 Yeah, 200, so that's 400 for the full year. You know, call it 100 times free cash flow. Still not, you know, god awful. That cash flow is going to double every year for a couple more years, which it probably will.
You know, it's pretty good. So, you know, I don't know, we'll have to see. It's one of these stocks you kind of have to pay attention to. Last night, Memory Stocks got crushed. Hynix reported what I thought was a really good quarter. Stock was down 10% anyway, but Micron went down right with it, but it came right back up, and Hynix is not even down in America.
So Bloom is up 10
So basically, you know, Western Digital and Seagate are up. Seagate had a good quarter. Intel's up a little.
I think the great semi-capitulation sell-off of July 2026 is over, but all the sellers are gone. The bears are gloating. I was talking to a bear last night. He was pounding his chest, gorilla style. He said, I'm King Kong. And I was like, all right, all right, all right. You know, the bears certainly got it, but the bulls have to get a little time in the sun too. And they certainly got it before. So Procesa Pharma does a reverse merger for BTK inhibitor.
I thought that was interesting. Lemonade stock down 17%.
Vertiv, that's what I want to look at. They do tools for data centers as well. Teradyne up 13%, but I think Clack had the down only, down 8%, kind of rough quarter there. We have the Capricor Adcom starting in nine minutes. That should be interesting. I have an 11 o'clock meeting, so I'm gonna take a half an hour for that. Earning season in full swing for the second quarter of 2026 Amphenol, very interesting company, Amphenol. It's not gone down one whit. I used to watch these guys 20 years ago. Betstacks, what's up? I didn't really understand the Adicet, what the situation was. It didn't look interesting to me, but let me take a second glance, just because I promised you I'd look at it. I keep my promises. $8.20.
It's a trading below cash. This is a cell therapy. I think there are a number of these Gamma Delta companies trying to do, I guess they're doing Lupus. So it's open label Lupus data we're excited about here. Lupus kind of comes and goes, so it's a rough one to get excited about, because disease flares, you know, the SLED-I, BLAG scores, at least when I was a kid, those were the Lupus measurement scores.
So if those are still the measurement scores, they are really kind of meaningless. 20 patients, you know, interim data is kind of meaningless, and they have a cancer thing. Yeah, it's just a cart thing that they're spending a lot of money on, that, you know, Lupus nephritis, I know a little bit about, you know, you can get the prognuria down, that's good. Treatment refractory RA, that's a little more interesting. And they're using lympho depletion? Well, that's a little weird. I mean, so this is it. This is with myeloablation, which is a bit of a bizarre, it's pretty, you know, pretty serious for autoimmune disease. You're going to try to kill the guy with this. These are for, this is for cancer, you know? No, it's interesting for sure. I definitely don't. Cell therapy for, certainly cell therapy for autoimmune is a cool idea. It's just a question of, you know, will it happen? Does it make sense? Or whom? Can you see that response in humans that's undeniable? It's not going to be so easy, but we look forward to this data. I mean, this is going to be interesting. Yeah, I mean, if you got some good results, I mean, look, you know, AbbVie has made a $500 billion company selling autoimmune drugs. It's plenty of patients, a lot of unmet need, you know? Will they myoablate or cell transplant? That's a little excessive. That's worse than the disease itself. You'll be a little careful of that, but you don't need myoablation, then you're good to go. But the problem is, you know, if they're your own cells and they don't expand, then it's a drop in the buck. It's not going to really help you. If it's somebody else's cells, you need matching and myoablation. We'll look at Biohaven 2 I'm not sure if Spruce Hustler is more. I can redo a refresh. Yeah, it's not so much about the huge market. Of course it's huge. It's much more about, you know, how does this, how could it work? Is it even possible, really? Because if you're doing it with myoablation, you're really dealing with people who are very sick. I mean, they would have to be so sick to want to do myoablation, which risks their life. You know, that is a life-threatening, you know, thing to go through. Now, some people are doing it for sickle cell, which is bad enough. So, you know, could there be, you know, a handful of patients that, and, you know, because it's a big market, a handful of patients could be thousands of patients a year that are so bad with RA, they're crippled. You know, maybe. Ah, I don't think they should prosecute Fauci, to be honest, and I don't like the guy. When you bring the full weight of the federal government on a single individual, you know, that makes me want to root for the individual. I like the underdog, you know, even if he was, you know, not the best guy. I'm also a softy. I'm Christian, I'm a softy. I forgive my enemies. It's one of my biggest weaknesses.